Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.46 |
| ▸ | SLC5A7 | Q9GZV3 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3288175 | 0.83 | OPRK1 (0.46) | PRMT6CARM1HRH3SLC5A7SMN1; SMN2 | |
| SCHEMBL4666227 | 0.82 | DRD2 (0.47) | UTS2RSLC5A7SMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4228960 | 0.82 | SMN1; SMN2 (0.48) | PRMT6CARM1HRH3SLC5A7SMN1; SMN2 | |
| SCHEMBL12696890 | 0.82 | DUT (0.47) | PRMT6CARM1HRH1 | |
| SCHEMBL4770681 | 0.81 | SMN1; SMN2 (0.46) | PRMT6CARM1HRH3UTS2RSLC5A7 | |
| SCHEMBL4664223 | 0.81 | KDM4E (0.58) | PRMT6CARM1HRH3UTS2RSLC5A7 | |
| SCHEMBL4228506 | 0.81 | SLC6A2 (0.58) | PRMT6CARM1OPRK1 | |
| SCHEMBL4228503 | 0.81 | SLC6A2 (0.58) | PRMT6CARM1OPRK1 | |
| SCHEMBL4666177 | 0.80 | SLC5A7 (0.46) | HRH3UTS2RSLC5A7SMN1; SMN2MEN1 | |
| SCHEMBL12408709 | 0.80 | FFAR4 (0.44) | PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076064-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076064-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076064-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1891065-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2007078251-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006130075-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076064-A1 | Compounds | CEL, PLA2G2D, CCKBR | PRMT6 1987/4885CARM1 3006/4885HRH3 288/4885 |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | MCHR1, MCHR2, HCRTR1 | PRMT6 436/4885CARM1 761/4885HRH3 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.